Nkarta CEO Paul Hastings at Endpoints' #BIO22 panel (J.T. MacMillan Photography for Endpoints News)

Nkar­ta un­der­scores safe­ty of CAR-NK, boasts ear­ly re­spons­es

The first gen­er­a­tion of per­son­al­ized CAR-T ther­a­pies made big waves in the treat­ment of lym­phoma for their stun­ning ef­fi­ca­cy. Nkar­ta is hop­ing its off-the-shelf nat­ur­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.